About GeneType - geneType™
menu

About geneType

geneType™ is a world-leading portfolio of personalised predictive tests that combines genomic and clinical information to forecast an individual’s risk of developing chronic diseases. This innovative approach empowers both patients and healthcare providers to take proactive steps toward better health outcomes, ushering in a new era of personalised medicine. 

The geneType™ portfolio also includes our patented Multi Risk Test (MRT) that assesses multiple conditions simultaneously.   

Since its 2021 launch in the US and Australia, the Multi Risk Test has delivered remarkable results, 40% of adults were identified as at increased risk for at least 1 of the diseases on the MRT. Nearly half of those identified did not have a family history of the disease. Our clinical performance has been well-established through peer-reviewed publications, demonstrating significant advances in risk detection. 

geneType™ represents the cutting edge of predictive diagnostics with patents both granted and pending across five patent families in key global geographical jurisdictions. We’re rapidly gaining commercial traction with medical providers and payers, with several key partnerships nearing finalisation. 

Building a future where cancer is identified early and treated effectively.

Rhythm Biosciences is transforming cancer diagnostics through innovative diagnostic technologies that predict, detect, characterise, and support early intervention. Our mission goes beyond testing, we’re creating a comprehensive approach to understanding cancer risk, enabling earlier treatment, and ultimately saving lives.

 

Leading Integrated Technology

Our personalised risk assessments provide a more complete picture, incorporating polygenic and clinical risk factors in one comprehensive assessment. 

We lead the way in clinical integration of polygenic risk by creating proprietary algorithms that are specifically calibrated to the general population. All of our disease-specific tests outperform their respective clinical gold-standard risk models. 

Our technology is designed to provide clinicians with absolute risk scores that simplify the complex integration of risk factors and ultimately enable actionable recommendations.   

geneType empowers individuals and their medical practitioners to adopt a personalised health approach to disease screening, risk-reduction and prevention. 

Pioneering excellence in genomic healthcare

The human impact and potential applications for genetic integration into clinical care are immense. We continue to expand our pipeline of clinical risk assessment products across multiple cancers and chronic conditions while setting new standards for quality and trust.  

We safeguard personal health data privacy and ensure every test delivers actionable outcomes with clear next steps. By leveraging innovative technology, software, and processes, we’re accelerating the world’s transition to genomic-integrated healthcare, delivering a more efficient, personalised model of care that adheres to rigorous clinical, safety, and ethical standards.